ACAD Downgraded by UBS -- Price Target Lowered to $23.00

gurufocus.com · 2026-10-13

Acadia Pharmaceuticals (ACAD) Downgraded by UBS: A Data-Driven Analysis On October 8, 2026, UBS has downgraded Acadia Pharmaceuticals (ACAD) from Buy to Neut

TickrTrends take: UBS's downgrade and price target reduction to $23 represents a notable shift in analyst sentiment for ACAD, which aligns with TickrTrends' current assessment that the stock is overvalued. For valuation-conscious investors monitoring the Healthcare sector, this analyst action reinforces the need to track whether the market reprices ACAD toward lower levels or if other fundamental factors might support current valuations. The convergence of the UBS downgrade with the overvalued designation suggests increased scrutiny around ACAD's near-term earnings power and growth prospects relative to its current market price.

Read the full story at gurufocus.com →